Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Ionis Pharmaceuticals (IONS) Shares Issued (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Shares Issued for 17 consecutive years, with $57.3 million as the latest value for Q1 2026.

For Q1 2026, Shares Issued rose 2456.98% year-over-year to $57.3 million; the TTM value through Mar 2026 reached $55.1 million, up 349.81%, while the annual FY2024 figure was $33.6 million, N/A changed from the prior year.
Shares Issued hit $57.3 million in Q1 2026 for Ionis Pharmaceuticals, up from -$84.8 million in the prior quarter.
Across five years, Shares Issued topped out at $489.1 million in Q3 2024 and bottomed at -$481.7 million in Q4 2024.
Average Shares Issued over 5 years is $5.3 million, with a median of $2.4 million recorded in 2023.
Year-over-year, Shares Issued crashed 603100.0% in 2022 and then soared 13012.6% in 2024.
Ionis Pharmaceuticals' Shares Issued stood at -$6.0 million in 2022, then plummeted by 43.95% to -$8.7 million in 2023, then plummeted by 5449.49% to -$481.7 million in 2024, then soared by 82.4% to -$84.8 million in 2025, then skyrocketed by 167.58% to $57.3 million in 2026.
According to Business Quant data, Shares Issued over the past three periods came in at $57.3 million, -$84.8 million, and $81.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.